financetom
Business
financetom
/
Business
/
N Chandra gets a 2nd term; experts decode the road ahead
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
N Chandra gets a 2nd term; experts decode the road ahead
Feb 11, 2022 9:31 AM

Tata Group's marathon man N Chandrasekaran gets another 5 years at the Bombay House corner office. The Tata Sons board has re-appointed him as the executive chairman for another five years. In a statement, Chandra said he was delighted at the opportunity.

An avid photographer who is fond of long-distance running, Chandra's elevation to the Tata Sons top job came in the aftermath of Cyrus Mistry's acrinomonious exit. Until then, Chandra, a trusted lieutenant of the Tatas, had helmed TCS, the crown jewel of the group.

But in the last five years with Chandra at the helm, Tata Group has seen rapid growth. The market cap of Tata companies have risen by 188 percent - it now stands at over 22 lakh crore.

Chairman emeritus Ratan Tata, a special invitee to the board meeting, expressed his satisfaction on performance of Tata Group under Chandra's leadership.

To discuss this CNBC-TV18’s Nisha Poddar spoke to Amit Chandra, Former Member of Tata Sons Board; Zia Mody, Founding & Senior Partner at AZB & Partners; Gopal Jain, Senior Lawyer of Supreme Court; VR Mehta, Former Trustee at Dorabji Tata Trust; and Vallabh Bhanshali, Chairman of ENAM Group.

For full interview, watch accompanying video.

Also Read: Tata Sons reappoints N Chandrasekaran as executive chairman for five years

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Thinkific Labs Closed Secondary Offering of Near $14.5 Million of Rhino Group's Shares
Thinkific Labs Closed Secondary Offering of Near $14.5 Million of Rhino Group's Shares
Jun 13, 2025
10:55 AM EDT, 06/13/2025 (MT Newswires) -- Thinkific Labs ( THNCF ) , a cloud-based software platform, on Friday closed the previously announced secondary bought deal offering of common shares in Thinkific ( THNCF ), held by the Rhino Group. A statement noted that the Rhino Group sold more than 6.4 million common shares at a price of C$2.25 each,...
Update: UK Regulator Mulls Releasing Google From Privacy Sandbox Commitments
Update: UK Regulator Mulls Releasing Google From Privacy Sandbox Commitments
Jun 13, 2025
10:53 AM EDT, 06/13/2025 (MT Newswires) -- (Updates with Google ( GOOG ) comment in the last paragraph.) The UK's Competition and Markets Authority began a consultation process on releasing Alphabet's (GOOG, GOOGL) Google ( GOOG ) from its commitments related to its Privacy Sandbox initiative, the regulator said Friday. The commitments were made to assure the CMA that Privacy...
FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer
FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer
Jun 13, 2025
The U.S. Food and Drug Administration (FDA) on Thursday approved UroGen Pharma Ltd.’s Zusduri, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Zusduri consists of mitomycin and sterile hydrogel, using UroGen’s proprietary sustained-release RTGel technology. Zusduri has been designed to treat potent tumor ablation. The FDA approval is based on the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved